Rockville-based Emergent BioSolutions Inc. on Friday announced the appointment of Barry Labinger, a well-known former executive at Human Genome Sciences Inc., to head its biosciences division.
Labinger served as HGS' chief commercial officer from 2005 until last year, when GlaxoSmithKline plc snapped up the Rockville drug-maker for $3.6 billion. Glaxo made a clean sweep of Human Genome executives, including CEO Tom Watkins, shortly after.